Literature DB >> 15708930

Immunopathology of psoriasis and psoriatic arthritis.

D J Veale1, C Ritchlin, O FitzGerald.   

Abstract

Psoriatic arthritis (PsA) is characterised by several unique clinical features that differentiate it from rheumatoid arthritis (RA). Attempts to identify immunopathological mechanisms, some shared with psoriasis, that underlie these differences from RA have been most challenging. Recent research studies, however, highlight novel findings in PsA at the molecular, cellular, and tissue levels that form the basis for a new understanding of this relatively common form of inflammatory arthritis. In particular, the availability of new, biological antitumour necrosis factor alpha therapies have allowed further insight into the immunopathology of psoriasis and PsA. This brief review focuses on immunohistological studies in psoriatic skin, PsA synovium, and bone to demonstrate how these data advance our knowledge of disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708930      PMCID: PMC1766860          DOI: 10.1136/ard.2004.031740

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  56 in total

1.  Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system.

Authors:  B J Nickoloff; B Bonish; B B Huang; S A Porcelli
Journal:  J Dermatol Sci       Date:  2000-12       Impact factor: 4.563

2.  Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis.

Authors:  L Laloux; M C Voisin; J Allain; N Martin; L Kerboull; X Chevalier; P Claudepierre
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

3.  Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C.

Authors:  R P Nair; P Stuart; T Henseler; S Jenisch; N V Chia; E Westphal; N J Schork; J Kim; H W Lim; E Christophers; J J Voorhees; J T Elder
Journal:  Am J Hum Genet       Date:  2000-05-05       Impact factor: 11.025

4.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.

Authors:  C L Danning; G G Illei; C Hitchon; M R Greer; D T Boumpas; I B McInnes
Journal:  Arthritis Rheum       Date:  2000-06

6.  The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602.

Authors:  S Gonzalez; J Martinez-Borra; J S Del Río; J Santos-Juanes; A Lopez-Vazquez; M Blanco-Gelaz; C López-Larrea
Journal:  J Invest Dermatol       Date:  2000-11       Impact factor: 8.551

Review 7.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

8.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

Authors:  J Lam; S Takeshita; J E Barker; O Kanagawa; F P Ross; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

9.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.

Authors:  E M Gravallese; C Manning; A Tsay; A Naito; C Pan; E Amento; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-02

10.  Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven.

Authors:  P J Costello; R J Winchester; S A Curran; K S Peterson; D J Kane; B Bresnihan; O M FitzGerald
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

View more
  43 in total

1.  Defining TNF-α- and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease.

Authors:  Biljana Smiljanovic; Joachim R Grün; Marta Steinbrich-Zöllner; Bruno Stuhlmüller; Thomas Häupl; Gerd R Burmester; Andreas Radbruch; Andreas Grützkau; Ria Baumgrass
Journal:  J Mol Med (Berl)       Date:  2010-07-17       Impact factor: 4.599

Review 2.  Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology.

Authors:  Philip Mease
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 3.  Genetics of susceptibility and treatment response in psoriatic arthritis.

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Nat Rev Rheumatol       Date:  2011-11-08       Impact factor: 20.543

Review 4.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

5.  Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.

Authors:  Franak M Batliwalla; Wentian Li; Christopher T Ritchlin; Xiangli Xiao; Max Brenner; Teresina Laragione; Tianmeng Shao; Robert Durham; Sunil Kemshetti; Edward Schwarz; Rodney Coe; Marlena Kern; Emily C Baechler; Timothy W Behrens; Peter K Gregersen; Pércio S Gulko
Journal:  Mol Med       Date:  2005 Jan-Dec       Impact factor: 6.354

6.  The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

Authors:  A Kavanaugh; C E Antoni; D Gladman; S Wassenberg; B Zhou; A Beutler; G Keenan; G Burmester; D E Furst; M H Weisman; J R Kalden; J Smolen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

7.  Classification and categorisation of psoriatic arthritis.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Clin Rheumatol       Date:  2008-07-16       Impact factor: 2.980

Review 8.  Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.

Authors:  Aizad Mumtaz; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

9.  Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent.

Authors:  Johannes Schwenck; Florian C Maier; Manfred Kneilling; Stefan Wiehr; Kerstin Fuchs
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

10.  Bone mineral density and bone turnover in patients with psoriatic arthritis.

Authors:  Pinar Borman; Seçil Babaoğlu; Guneş Gur; Sezin Bingol; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.